back

Dupilumab (new indication: eosinophilic esophagitis for patients ≥ 40 kg and ≥ 12 years of age)

 

Subject:

  • Active Substance: Dupilumab
  • Name: Dupixent®
  • Therapeutic area: Eosinophilic esophagitis
  • Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

 

Time table:

  • Start: 01.04.2023
  • Final decision by G-BA: 21.09.2023

 

Final decision:

  • No additional benefit proved